NEW YORK (360Dx) – Bio-Techne said today that it has inked a strategic agreement with Micropoint Bioscience, developer of a microfluidic chip for point-of-care testing based in Shenzhen, China.

Bio-Techne said that under the agreement, the firms will collaborate to strengthen the integration of its ProteinSimple Ella microfluidic instrument, a fully automated multianalyte immunoassay, to develop "better and more accurate" point-of-care diagnostic tools for the Chinese market.

Financial and other terms of the agreement were not disclosed.